Real-Life Effectiveness and Safety of Baricitinib as Adjunctive to Standard-of-Care Treatment in Hospitalized Patients With Severe Coronavirus Disease 2019.

Nikolaos-Renatos TziolosEmmanouil KarofylakisIoannis GrigoropoulosPinelopi KazakouEmmanouil KoulliasAthina SavvaHariklia KranidiotiAimilia PelekanouAnna BouloutaMaria PirounakiSotirios TsiodrasGeorgios GeorgiopoulosDimitrios T BoumpasDimitra KavathaKonstantinos ThomasDimitrios VassilopoulosAnastasia Antoniadou

Published in: Open forum infectious diseases (2021)

In real-life settings, addition of baricitinib to SOC in patients hospitalized with sCOVID-19 is associated with decreased mortality without concerning safety signals.

Keyphrases

coronavirus disease
end stage renal disease
healthcare
ejection fraction
newly diagnosed
peritoneal dialysis
type diabetes
early onset
coronary artery disease
quality improvement
replacement therapy